Загрузка...
Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
Evogliptin is a newly developed dipeptidyl peptidase-4 (DPP-4) inhibitor, which is expected to be combined with metformin for treating type 2 diabetes mellitus. We investigated the potential pharmacokinetic and pharmacodynamic interactions between evogliptin and metformin. A randomized, open-label,...
Сохранить в:
| Опубликовано в: : | Drug Des Devel Ther |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4986685/ https://ncbi.nlm.nih.gov/pubmed/27570447 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S110712 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|